SELLAS Life Sciences Group, Inc. (SLS): Price and Financial Metrics

SELLAS Life Sciences Group, Inc. (SLS)

Today's Latest Price: $3.40 USD

0.09 (-2.58%)

Updated Aug 11 3:05pm

Add SLS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

SLS Daily Price Range
SLS 52-Week Price Range

SLS Stock Price Chart Technical Analysis Charts

SLS Price/Volume Stats

Current price $3.40 52-week high $10.89
Prev. close $3.49 52-week low $1.46
Day low $3.36 Volume 64,032
Day high $3.53 Avg. volume 377,008
50-day MA $3.23 Dividend yield N/A
200-day MA $3.27 Market Cap 22.84M

SELLAS Life Sciences Group, Inc. (SLS) Company Bio

SELLAS Life Sciences, Ltd. is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.

SLS Latest News Stream

Event/Time News Detail
Loading, please wait...

SLS Latest Social Stream

Loading social stream, please wait...

View Full SLS Social Stream

Latest SLS News From Around the Web

Below are the latest news stories about SELLAS Life Sciences Group Inc that investors may wish to consider to help them evaluate SLS as an investment opportunity.

Solaris to Begin Trading on TSX Venture Exchange (TSXV: SLS)

VANCOUVER, BC , July 8, 2020 /CNW/ - Solaris Resources Inc. (TSXV: SLS) ("Solaris" or the "Company") is pleased to announce that its common shares have been approved for listing on the TSX Venture Exchange under the symbol "TSXV: SLS". This document contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements").

Yahoo | July 8, 2020

SELLAS Life Sciences Advancing Its Innovative Immunotherapy Across Phase 1, 2 and 3 Studies and in Collaboration with Big Pharma; Data Demonstrates Increase in Survival

Jun 29, 2020 (AB Digital via COMTEX) -- As the United States enters nearly its fifth month in the global fight against COVID-19, many investors have set…

MarketWatch | June 29, 2020

Targeting The National Cancer Institute's #1- Ranked Cancer Antigen: SELLAS' Most Advanced Immunotherapy in Pivotal Phase 3 Study in AML and in Phase 1/2 Studies in Combination With PD1

New York, New York--(Newsfile Corp. - June 23, 2020) - As the United States enters nearly its fifth month in the global fight against COVID-19, many investors have set their eyes on companies racing to discover a cure and restore things back to a sense of normalcy. But despite this new threat to public health, cancer never paused for a pandemic. That's why savvy investors and healthcare professionals alike continue to focus on the ...

Yahoo | June 23, 2020

Solaris Advances Conditional Listing Approval; Closes C$1.2M Placement with Lundin

VANCOUVER, BC , June 11, 2020 /CNW/ - Solaris Resources Inc. ("Solaris" or the "Company") is pleased to announce advancement of the conditional approval received from the TSX Venture Exchange (the "Exchange") for listing of its shares on the Exchange as a Tier 2 issuer under the symbol "TSXV: SLS". Subject to fulfillment of customary conditions, the listing is expected to occur in the third quarter. No public offering of shares is anticipated in connection with the listing.

Yahoo | June 11, 2020

SELLAS to Host Virtual Annual Meeting of Stockholders

The date and time of the Annual Meeting, as disclosed in the previously distributed Notice of the Annual Meeting and Definitive Proxy Statement (the "Notice and Proxy Statement"), has not changed. Stockholders of record and registered beneficial owners as of the close of business on April 13, 2020 will be able to vote and ask questions during the meeting through the online platform. Stockholders will not be able to attend the Annual Meeting in person.

Yahoo | May 22, 2020

Read More 'SLS' Stories Here

SLS Price Returns

1-mo 14.48%
3-mo 22.74%
6-mo 21.00%
1-year -58.02%
3-year -99.33%
5-year -99.99%
YTD -20.93%
2019 -93.01%
2018 -84.23%
2017 -86.60%
2016 -93.40%
2015 -2.65%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7993 seconds.